Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) have been given an average rating of “Moderate Buy” by the twenty-one brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eighteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $251.2632.

A number of equities analysts recently weighed in on AXSM shares. Jefferies Financial Group upped their target price on shares of Axsome Therapeutics from $245.00 to $275.00 and gave the stock a “buy” rating in a research note on Monday, May 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $272.00 price target on shares of Axsome Therapeutics in a research note on Monday, May 4th. Royal Bank Of Canada lifted their price target on Axsome Therapeutics from $242.00 to $302.00 and gave the company an “outperform” rating in a research note on Tuesday, May 5th. Oppenheimer set a $280.00 price target on Axsome Therapeutics in a research note on Monday, May 4th. Finally, UBS Group lifted their price target on Axsome Therapeutics from $251.00 to $259.00 and gave the company a “buy” rating in a research note on Friday, April 10th.

Insider Activity

In other Axsome Therapeutics news, insider Ari Maizel sold 7,500 shares of Axsome Therapeutics stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $182.42, for a total value of $1,368,150.00. Following the sale, the insider owned 7,500 shares of the company’s stock, valued at $1,368,150. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Mark L. Jacobson sold 233 shares of Axsome Therapeutics stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $228.18, for a total value of $53,165.94. Following the completion of the sale, the chief operating officer directly owned 4,517 shares in the company, valued at $1,030,689.06. This represents a 4.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 12,250 shares of company stock worth $2,450,921 in the last three months. Company insiders own 20.60% of the company’s stock.

Institutional Trading of Axsome Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Kemnay Advisory Services Inc. bought a new stake in Axsome Therapeutics during the 4th quarter worth about $31,000. Hollencrest Capital Management lifted its position in Axsome Therapeutics by 400.0% during the 1st quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock worth $34,000 after buying an additional 160 shares in the last quarter. Optiver Holding B.V. lifted its position in Axsome Therapeutics by 82.3% during the 3rd quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock worth $35,000 after buying an additional 130 shares in the last quarter. Ameriflex Group Inc. bought a new stake in Axsome Therapeutics during the 4th quarter worth about $37,000. Finally, Essex Investment Management Co. LLC bought a new stake in Axsome Therapeutics during the 3rd quarter worth about $38,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Trading Up 0.7%

Shares of NASDAQ AXSM opened at $234.48 on Friday. The company’s fifty day moving average is $195.53 and its 200-day moving average is $175.25. The stock has a market cap of $12.07 billion, a price-to-earnings ratio of -62.86 and a beta of 0.59. Axsome Therapeutics has a twelve month low of $96.09 and a twelve month high of $238.56. The company has a quick ratio of 1.32, a current ratio of 1.39 and a debt-to-equity ratio of 2.27.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). The firm had revenue of $191.20 million for the quarter, compared to the consensus estimate of $191.10 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.Axsome Therapeutics’s revenue for the quarter was up 57.4% compared to the same quarter last year. Equities research analysts predict that Axsome Therapeutics will post -2.14 EPS for the current year.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.